Sinopharm, a state-controlled company, said its candidate had a 79 percent efficacy rate in interim late-stage trials, bringing a China-made vaccine a step closer to approval for mass use.
from NYT > Top Stories https://ift.tt/34XwraO
https://ift.tt/eA8V8J
No comments:
Post a Comment